A naukri.com initiative
Bioengineer
2w
116
Image Credit: Bioengineer
Menarini Group and Insilico Medicine Forge Second Exclusive Global License for AI-Developed Preclinical Oncology Asset Addressing Unmet Medical Needs
- Menarini Group and Insilico Medicine have entered into an exclusive licensing agreement for a preclinical small molecule aimed at solid tumor malignancies, which is designed through generative AI methodologies.
- The deal highlights the trend towards integrating artificial intelligence in drug discovery, and is Menarini's second asset from Insilico Medicine.
- The compound has demonstrated broad anti-tumor activity in preclinical studies, indicating its potential strength as a therapeutic agent, adaptability in targeting complex cancer profiles, and likeliness of success in drug development.
- The collaboration allows the consolidation of resources and expertise, and is poised to exceed $550 million in total projected value when factoring in development, regulatory, and milestone payments.
- Both Menarini and Insilico Medicine express enthusiasm over the potential of advanced technology to revolutionize drug discovery and treatment outcomes.
- Generative AI capabilities are revolutionizing the landscape of drug discovery.
- The partnership between Menarini and Insilico Medicine enhances the therapeutic arsenal available to oncologists, highlighting the importance of adaptability in research initiatives toward improving patient outcomes.
- The agreement marks a potential paradigm shift in the way cancer therapies are developed and delivered to patients, using dynamic collaboration between AI technology and conventional pharmaceutical practice.
- The integration of machine learning and deep generative models enables a more holistic approach to identify new drug targets and generate molecules with specific desired characteristics.
- The achievement could indicate that AI may become an indispensable partner in future drug development endeavors, charting pathways not previously considered feasible through standard procedures.
Read Full Article
7 Likes
For uninterrupted reading, download the app